Materias dentro de su búsqueda.
Mostrando 1,601 - 1,620 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.45s Limitar resultados
  1. 1601
    “…Accurate and timely assessment of the HER2/neu over expression is pivotal for the identification of breast cancer patients that could benefit from HER2-targeted therapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparison of Her2/Neu Oncoprotein in Serum and Tissue Samples in Women with Breast Cancer
  2. 1602
    “…The prognostic performance of PREDICT in patients with HER2-positive early breast cancer (EBC) treated in the modern era with effective chemotherapy and anti-HER2 targeted therapies is unclear. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
  3. 1603
    “…In this review, we report and discuss new findings on the impact of the gut and breast microbiota on BC, focusing on the HER2+ BC subtype, and the possibility of defining microbial signatures that are associated with disease aggressiveness, treatment response, and therapy toxicity. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine
  4. 1604
    “…RECENT FINDINGS: Patients with TN and HER2 + breast cancer with excellent response to NACT would be the ideal candidates for surgical de-escalation. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer
  5. 1605
    “…A combination MMP-9 biomarker with HER2 and Ki-67 is expected to provide more specificity in prognosis for better breast cancer (BC) treatment options. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Matrix Metalloproteinase-9 as Prognostic Factor for the Treatment of HER-2 Enriched Breast Cancer
  6. 1606
    “…SIMPLE SUMMARY: HER2-low breast cancer (BC) accounts for more than half of breast cancer patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions
  7. 1607
    “…Although ERBB2 (also known as HER-2) has an important therapeutic role in breast and esophagogastric cancer, there are no approved ERBB2-targeted therapies for mCRC. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene
  8. 1608
    por Lucas, Mairi W, Kelly, Catherine M
    Publicado 2022
    “…If neoadjuvant chemotherapy is given for high-risk HR-positive, HER2-negative breast cancer, standard adjuvant anthracycline/taxane regimens are appropriate. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights
  9. 1609
    “…To evaluate the cardiac safety of anti-HER2-targeted therapy for early breast cancer; to investigate whether trastuzumab combined with pertuzumab increases cardiac toxicity compared with trastuzumab; to evaluate the predictive value of high-sensitivity Troponin (hs-TnI) and QTc for the cardiotoxicity associated with anti-HER2 targeted therapy in early breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer
  10. 1610
    “…BACKGROUND: HER2-positive breast cancers are rare amongst BRCA mutation carriers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer
  11. 1611
    “…In this study, using breast cancer cell lines, we show that the HER receptor ligands, EGF and neuregulin (NRG-1β), as well as the phorbol ester, PMA, can increase the expression of EGFR isoform D, as well as isoform A. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells
  12. 1612
    “…BACKGROUND: The “HER2-low” nomenclature identifies breast carcinomas (BCs) displaying a HER2 score of 1+/2+ in immunohistochemistry and lacking ERBB2 amplification. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas
  13. 1613
    “…Human epidermal growth factor receptor type 2 (HER2)-positive BC accounts for 14.5–15% of all BCs, with a relatively poor prognosis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Advances in neoadjuvant therapy for HER2-positive breast cancers: a narrative review
  14. 1614
    “…SIMPLE SUMMARY: There are growing data on targeting HER2 alterations, which include gene mutations, gene amplifications, and protein overexpression, for non-small cell lung cancer (NSCLC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies
  15. 1615
    “…HER2-targeted therapy can be recommended prior to ADT for HER2-positive/AR-positive SDC. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma
  16. 1616
    por Vial, Andrea C., Cowgill, Colleen M.
    Publicado 2022
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Heavier Lies Her Crown: Gendered Patterns of Leader Emotional Labor and Their Downstream Effects
  17. 1617
    por Dantu, Siva, Khan, Asama, Dhir, Mashaal
    Publicado 2022
    “…He demonstrated increased HER2 expression and was placed on dual HER2 antagonists. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Role of dual anti-HER2 therapy before liver resection for rectal metastases
  18. 1618
    “…MXenes, a novel family of 2D transition metal carbide, nitride and carbonitride materials, have been gaining tremendous interest in recent days as potential electrocatalysts for various electrochemical reactions, including hydrogen evolution reaction (HER). MXenes are characterized by their etchable metal layers, excellent structural stability, versatility for heteroatoms doping, excellent electronic conductivity, unique surface functional groups and admirable surface area, suitable for the role of electrocatalyst/support in electrochemical reactions, such as HER. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2D MXene Nanomaterials as Electrocatalysts for Hydrogen Evolution Reaction (HER): A Review
  19. 1619
    “…Breast cancer is one of the most common malignancies and the leading cause of cancer-related death in women. HER2 overexpression is a factor for poor prognosis in breast cancer, and anti-HER2 therapy improves survival in these patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies
  20. 1620
    “…Human Epidermal Growth Factor Receptor 2 (HER2) overexpression is considered one of the interesting prognostic biomarkers in bladder cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Interaction between HER2 and ATM predicts poor survival in bladder cancer patients
Herramientas de búsqueda: RSS